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Summary
Background: Infection with the human immunodeficiency virus (HIV) is associated
both with infections of the central nervous system and with neurological deficits due
to direct effects of the neurotropic virus. Seizures and epilepsy are not rare among
HIV-infected patients. We investigated the frequency of acute seizures and epilepsy of
patients in different stages of HIV infection. In addition, we compared the char-
acteristics of patients who experienced provoked seizures only with those of patients
who developed epilepsy.
Methods: The database of the Department of Neurology, University of Mu¨nster, was
searched for patients with HIV infection admitted between 1992 and 2004. Their
charts were reviewed regarding all available sociodemographic, clinical, neurophy-
siological, imaging and laboratory data, therapy and outcome. Stage of infection
according to the CDC classification and the epileptogenic zone were determined.
Results: Of 831 HIV-infected patients treated in our department, 51 (6.1%) had
seizures or epilepsy. Three of the 51 patients (6%) were diagnosed with epilepsy
before the onset of the HIV infection. Fourteen patients (27%) only had single or few
provoked seizures in the setting of acute cerebral disorders (eight patients), drug
withdrawal or sleep withdrawal (two patients), or of unknown cause (four patients).
Thirty-four patients (67%) developed epilepsy in the course of their HIV infection.
Toxoplasmosis (seven patients), progressive multifocal leukencephalopathy (seven
patients) and other acute or subacute cerebral infections (five patients) were the* Corresponding author at: Department of Neurology, Klinikum Osnabru¨ck, Am Finkenhu¨gel 1, 49076 Osnabru¨ck, Germany.
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Infection with the human immunodeficiency virus
(HIV) carries a risk for seizures through opportunistic
infections of the central nervous system (CNS).
Toxoplasmosis, CNS lymphoma, cryptococcal or
tuberculous meningitis, and progressive multifocal
leukencephalopathy (PML) are strongly associated
with the occurrence of acute or chronic repeated
seizures.1—4 In addition, the HIV is neurotropic and
thus may have direct harmful effects on the CNS
itself.5 Moreover, drugs used for treatment of the
HIV infection6 or opportunistic infections,7 and
metabolic abnormalities associated with renal or
hepatic failure8 may predispose for seizures.
Data about the frequency of seizures among HIV-
infected patients are limited by the retrospective
design and small sample sizes of most studies. New
onset seizures were found in 3—17% of the inves-
tigated patient group.1,4,8—11 Since most studies
have focussed on new onset seizures, even less is
known about the frequency of pre-existing epi-
lepsy in HIV-infected persons. The prevalence of
epilepsy in the normal population is age depen-
dent. In the age group 20—40 years, estimated
prevalence for epilepsy in the normal population
is 20—40/100,000.12 The few studies documenting
all patients with seizures in a defined group of HIV-
infected patients found that in 1—4% of the cases
the seizures clearly predated the HIV infec-
tion.9,10,4 However, these patients were recruited
in hospitals and not in the community where the
prevalence of epilepsy among HIV-infected persons
may be lower.
Inmost studies, themajority of patients suffered
primarily from generalized seizures with only
25—30% showing focal symptoms.1,4 Focal seizures
were not necessarily associated with focal space-
occupying lesions.Seizures in HIV-infected patients seem to have a
high chance of recurrence,9 therefore, it has been
recommended to start anticonvulsant therapy even
after the first seizure.13 Phenytoin and carbamaze-
pine are strong inducers of the hepatic cytochrome
p450 system. Since many antiretroviral agents are
substrates of this enzyme system, administration of
these drugs results in unfavorable pharmacokinetic
interactions and thus in failure of antiretroviral
therapy.14 The newer anticonvulsant agents like
gabapentin, lamotrigine and levetiracetam do not
have most of these disadvantages and are therefore
recommended for use in HIV-associated seizures.13
With our study, we wanted to investigate the char-
acteristics of HIV-infected patients with seizures or
epilepsy, and to compare those patients who only
had provoked seizures with patients who eventually
developed epilepsy, and to document the treatment
that had been prescribed.Methods
The database of the Department of Neurology, Uni-
versity of Mu¨nster, was searched for patients with
HIV infection treated as in-patients or out-patients
between 1992 and 2004. The Department of Neurol-
ogy is a referral center for HIV-infected patients
with neurological symptoms and part of the ‘com-
petence network HIV’ in Germany. Patients with a
history of seizures or with seizures during treatment
were identified by searching for the keyword ‘sei-
zure/seizures’ and ‘epilepsy’ in the computerized
database as well as in the patients’ discharge sum-
maries. The charts of all identified patients were
reviewed using all available historical, sociodemo-
graphic, clinical, neurophysiological, imaging and
laboratory data. The diagnosis of seizures or epi-
lepsy was verified, patients with inconclusive datamost frequent causes of seizures. EEG data of 38 patients were available. EEG showed
generalized and diffuse slowing only in 9 patients, regional slowing in 14 patients and
regional slowing and epileptiform discharges in 1 patient. Only 14 of the patients had
normal EEG. At the last contact, the majority of the patients (46 patients = 90%) were
on highly active antiretroviral therapy (HAART). Twenty-seven patients (53%) were on
anticonvulsant therapy (gabapentin: 14 patients, carbamazepine: 9 patients, valpro-
ate: 2 patients, phenytoin: 1 patient, lamotrigine: 1 patient). Patients with only
provoked seizures had no epilepsy risk factors except HIV infection, and were less
likely to be infected via intravenous drug abuse.
Conclusions: Seizures are a relevant neurological symptom during the course of HIV
infection. Although in some patients seizures only occur provoked by acute disease
processes, the majority of patients with new onset seizures eventually develops
epilepsy and require anticonvulsant therapy. Intravenous drug abuse and the presence
of non-HIV-associated risk factors for epilepsy seem to be associated with the
development of chronic seizures in this patient group.
# 2007 British Epilepsy Association. Published by Elsevier Ltd. All rights reserved.
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Table 1 Demographic and clinical characteristics of
all HIV-infected patients with seizures
HIV-infected patients
with seizures or
epilepsy (n = 51)
Age in years (median,
25/75 percentile)
37, 31/41
Sex (female/male) 13/38
CDC stage at time of first seizure
A 0
B 2
C 29
Epilepsy onset before infection3
Not classifiable 17
Way of infection
Sexual contact 13
i.v. drug abuse 10
Blood/transplantation 6
Other 1that did not allow certain diagnosis were excluded.
Information about seizure therapy and outcome was
gathered. Stage of infection according to the Center
of Disease Control (CDC) classification, time of
infection and way of infection, the seizure type,
the epileptogenic zone and the etiology of epilepsy
were determined using all available information.
HIV-associated encephalopathy was diagnosed when
the appropriate clinical features were present and
other causes for encephalopathic symptoms could
be excluded.
Statistical analysis was performed with a
commercial software package (SPSS 12.0 for win-
dows, SPSS Inc., Chicago, IL, USA). Interval- and
ordinal-scaled data were compared using the
Mann—Whitney U-test for inter-group comparison,
nominal-scaled data with the x2-test or Fisher’s
exact test (2  2 tables). Significance level was
set at p < 0.05 for two-tailed tests.Unknown 21
CD4+ lymphocytes at time of first seizure
>500 6
200—500 9
<200 18
Unknown 18
HAART at time of first seizure
Yes 37
No 4
Not applicable 3
Unknown 7
CNS complications at time of first seizure
HIV-associated encephalopathy11
Toxoplasmosis 7
PML 7
CNS-tuberculosis 1
None/unknown/not applicable 25Results
During the study period, 831 HIV-infected patients
were treated as in-patients in our department.
Fifty-one of them (6.1%) had seizures or epilepsy
and will be described further. Their median age was
37 years, and more than two-third of them were
male (Table 1). In three patients (6%), seizure onset
clearly predated the HIV infection. Fourteen
patients (27%) had single or few seizures only in
the setting of acute disease (eight patients), drug
withdrawal or sleep withdrawal (two patients), or of
unknown cause (four patients). The other 38
patients (67%) eventually developed epilepsy. Thus,
the incidence of new onset seizures in our patient
cohort was 5.8%. The patients’ characteristics are
presented in Table 1. The most frequent underlying
cerebral diseases were HIV-associated encephalo-
pathy (11 patients), PML (7 patients) and toxoplas-
mosis (7 patients).
Eight patients (17%) had simple partial seizures
only, three patients (6%) had complex partial sei-
zures only. Partial seizures with secondary general-
ization were seen at least once in 14 patients (27%).
In 26 patients (51%), the seizure was generalized
without definite partial component. Electroence-
phalography (EEG) data was available for 38
patients. The other 13 patients had undergone
EEG at other institutions. Fourteen patients (27%)
had a normal EEG, in nine patients (17%) only gen-
eralized slowing was detected. The EEG of 3
patients (6%) showed generalized as well as regional
slowing, 11 patients (22%) had only regional slowing,
1 patient showed additional regional epileptiform
discharges. Cerebral imaging data computedtomography (CT) and magnetic resonance imaging
(MRI) was available for 44 patients. The majority of
them had a cortical lesion, only 10 had no visible
lesion in the CTor MRI scan (see Table 2). Out of the
37 patients with (pre-existing or new onset) epi-
lepsy, the epileptogenic zone could be localized to a
certain brain region in only 6 patients. The diagnosis
of non-localizable focal epilepsy was made in 11
patients. In 20 patients, the epilepsy could not be
further classified.
The patients with new onset epilepsy did not
differ from the patients who only had single or
few provoked seizures regarding age and gender
distribution, CDC stage at time of first seizure,
CD4+ lymphocyte count, highly active antiretroviral
therapy (HAART) at time of first seizure, EEG or
imaging abnormalities or seizure classification
(see Table 3). No patient with only provoked
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Table 2 Classification and seizure-related data in all
HIV-infected patients with seizures
HIV-infected
patients with
seizures or
epilepsy (n = 51)
Epilepsy classification
Epilepsy (unclassifiable) 20
Focal epilepsy (non-localizable) 11
Focal epilepsy (extratemporal) 6
Single seizure 14
Seizure classification
Simple partial seizure 8
Complex partial seizure 3
Partial seizure with secondary
generalization
14
Generalized seizure (unclassifiable)26
Risk factor for epilepsy besides HIV-associated risks
No risk factor/unknown 42
Head trauma 2
Positive family history 1
Brain surgery 1
EEG
Alcohol-/drug abuse 5
Normal 14
Generalized slowing only 9
Focal slowing only 11
Focal and generalized slowing 3
Focal slowing and epileptiform
discharges
1
No original EEG data available 13
Imaging (MRI, CT scan)
No lesion 20
Cortical lesion 21
Subcortical lesion only 3
No imaging data available 7seizures was infected via intravenous drug abuse
( p < 0.05) or had other than HIV-associated risk
factors for epilepsy (p = 0.09), and only one of them
had HIV-associated encephalopathy as the only CNS
manifestation of HIV infection.
At the time of last contact to our center, 29 of the
51 patients (57%) were on anticonvulsant therapy
(see Table 4). The most frequently used substance
was gabapentin (14 patients) followed by carbama-
zepine (9 patients).Discussion
Seizures and epilepsy are a relevant neurological
symptom or sequela in HIV-infected patients that
frequently occur in acute disease setting. In most
patients, cerebral imaging shows cortical lesions.
However, not all patients who develop acuteseizures eventually develop epilepsy. Common epi-
lepsy risk factors and intravenous drug abuse were
associated with recurrent chronic seizures.
Although the majority of the patients were treated
with anticonvulsants, a significant number did not
receive the best-suited substances.
The prevalence of seizures or epilepsy in our
study cohort is similar to the more recently pub-
lished reports. Pascual-Sedano and coworkers
reported 3% patients with new onset seizures among
HIV-infected patients of an internal medicine refer-
ral center in Spain.1 A study performed in a tertiary
care hospital in India documented new onset sei-
zures in 8% of all HIV-infected patients.9 On the
other hand, a study reporting data from the mid-
1980s found a significantly higher incidence of 11%,4
another early study of even 17%.11 Most likely, the
cohorts of earlier series were suffering from more
advanced stages of the disease due to the more
restricted therapeutic means at that time.
Intracranial cortical lesions were found in more
than 40% of our patients. This proportion is slightly
higher than reported by Wong et al.4 and Dore
et al.,10 but approximately similar to that of Van
Paesschen et al.8 Cerebral toxoplasmosis accounted
for the majority of identifiable lesion etiologies.
This is in accordance with most other studies who
reported on lesional seizure etiology.1,4,8—10,15,16
The prevalence of toxoplasmosis in our as well as
other studies is relatively high. This is most likely
due to the change in antiretroviral and supporting
antiinfective therapy over the last years.17 Inter-
estingly, PML was found equally frequent in our
patients. Other studies found much less PML among
their seizure patients.1,9 Since these studies have
been performed in medical departments, PML might
have been underdiagnosed, and recruitment bias
may play an additional role.
The pathomechanisms causing seizures in PML as
a white matter disease remain to be elucidated.
Pathological studies have shown that demyelination
takes place not only in white matter, but also both in
cortical areas and the basal ganglia.18 Lesions adja-
cent to the cortex seem to be associated with the
occurrence of seizures in patients with PML.19 Neu-
rons affected by demyelination may alter their
electrophysiological properties and become hyper-
excitable, thus increasing the likelihood of sei-
zures.20 However, these hypotheses still need to
be verified.
HIV related encephalopathy was found in a rela-
tively large proportion of our patients. Similar
results were reported by Pesola and Westfal.21
and Holtzman et al.16 from western industrialized
countries, whereas two reports from India and South
Africa found only few patients with this symptom
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Table 3 Comparison of the characteristics in acute seizures vs. epilepsy with onset after infection
HIV-infected patients
with provoked
seizures (n = 14)
HIV-infected
patients with
epilepsy (n = 34)
Significance
Age in years (median, 25/75 percentile) 31, 28.5/50 37, 32/41 n.s.
Sex (female/male) 4/10 8/26 n.s.
CDC stage at time of first seizure
A 0 0 n.s.
B 0 2
C 11 18
Not classifiable 3 14
CDC at last contact
A 0 4 n.s.
B 0 3
C 12 23
Not classifiable 2 4
Way of infection
Sexual contact 6 6 p < 0.05 (i.v.-drug
abuse vs. no i.v.
-drug abuse)
i.v. drug abuse 0 10
Blood/transplantation 2 3
Other 0 1
Unknown 6 14
CD4+ lymphocytes
>500 0 6 n.s.
200-500 2 7
<200 7 11
Unknown 5 10
HAART at time of first seizure
Yes 9 26 n.s.
No 2 2
Not applicable/unknown 3 6
MRI lesion
No lesion 3 17 n.s.
Only subcortical 1 2
Cortical lesion 8 11
No imaging data available 2 4
Etiology of cerebral lesions
Toxoplasmosis 5 2 n.s.
PML 3 3
HIV-encephalopathy 1 10
Unknown/not applicable 5 19
EEG
Normal 4 10 n.s.
Generalized slowing only 5 4
Focal slowing, no ED 3 8
ED 0 1
No EEG data available 2 11
Seizure classification
Simple partial seizure 1 6 n.s.
Complex partial seizure 2 1
Partial seizure with secondary generalization 4 9
Generalized seizure (unclassifiable) 7 18
Risk factor for epilepsy besides HIV-associated risks
No/unknown 14 27 n.s. (p = 0.09)
Risk factor present 0 7
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Table 4 Anticonvulsant therapy
HIV-infected patients with
seizures and epilepsy (n = 51)
Anticonvulsant therapy at time of last contact
Yes 29
No 22
AED
Gabapentin 14
Valproate 2
Carbamazepine 9
Lamotrigine 1
Clonazepam 2
Phenytoin 1complex. HIV related encephalopathy usually occurs
in later stages of the infection, and patients in non-
industrialized countries may not live long enough to
develop this condition.
Although most patient had unspecific EEG
abnormalities, epileptiform discharges were seen
only in one patient. This supports the notion men-
tioned in earlier studies9,16,4 that EEG is relatively
insensitive in the setting of seizures associated with
HIV infection.
A clear focal semiology was seen in almost 50% of
our patients. Most other reports found focal semi-
ology in 15—30% of the cases,15,1,8,4 although the
proportion of identifiable focal brain lesions was
roughly similar. This discrepancy may be due to
recruitment bias. However, in our study, all chart
documents were reviewed by a trained epileptolo-
gist who might have been more aware of evidence
that proves partial seizure onset. Anyway, general-
ized seizures predominate in HIV patients.
Patients with provoked seizures differed from
patients who developed epilepsy only in some
aspects. Intravenous drug abuse was found only in
patients who developed epilepsy. This could be
explained by a higher proportion of opportunistic,
drug-related comorbidity in those patients, which
may predispose to the development of epilepsy.
Acknowledged risk factors for epilepsy in otherwise
healthy persons such as previous head trauma or
positive family history of epilepsy are of course
associated with the development of epilepsy also
in HIV-infected patients.
Anticonvulsant therapy was initiated in nearly
two third of our patients. Almost half of them were
on gabapentin, an anticonvulsant drug that is no
substrate or inducer of the cytochrome p450 sys-
tem, is not relevantly protein-bound and exclusively
renally eliminated, and therefore has essentially no
interactions with other drugs.22 In addition to its
anticonvulsant properties, it is anxiolytic and hasanalgesic effects in neuropathic pain.23 Therefore,
it is recommended for use in HIV-infected
patients.13,24 However, its effect on seizures in this
patient group has never been investigated in con-
trolled trials. Pregabalin and Levetiracetam are new
anticonvulsant agents with equally favorable phar-
macokinetics. Carbamazepine is effective in focal
epilepsy, but — as inducer as well as substrate of the
cytochrome p450 system — potentially has unfavor-
able pharmacokinetic properties, particularly when
used in combination with HAART. On the one hand,
HAART failure due to carbamazepine interaction has
been reported.14 On the other hand, carbamazepine
toxicity may be increased by antiretroviral
agents.25,26 Two of eight HIV-infected patients
treated with carbamazepine had to switch therapy
because of side effects.15 Phenytoin has the
same unfavorable pharmacokinetic properties. In
patients with HIV-associated seizures, 14% of the
patients treated with phenytoin had to discontinue
due to side effects.16 Other studies1,9 did not find
serious side effects from phenytoin treatment but
had only limited follow-up. Thus, a relevant number
of patients were treated with agents with high
potential of complications although more favorable
drugs are available. In most cases, initial anticon-
vulsant treatment was initiated by a general prac-
ticioner or internal medicine specialist. These
clinicians may not be aware of the high potential
for adverse effects of these drugs among HIV-
infected patients. In addition, a relevant number
of cases were treated before gabapentin or one of
the other favorable agents became available.
Valproate acid is used in focal as well as general-
ized epilepsy. It was administered in two of our
patients. Until recently, its use has been discour-
aged because of in vitro data suggesting a drug-
induced increase of viral replication.27 However, it
has been discovered that valproate inhibits a chro-
matin remodeling enzyme responsible for mainte-
nance of latent HIV infection in CD4+ T-cells.28 A
small pilot study could show that three of the four
patients had significant decrease of latent HIV infec-
tion in resting T-cells under valproate therapy in
combination with HAART.29 If these preliminary
results can be reproduced in larger studies, valpro-
ate could become an anticonvulsant of first choice in
HIV-infected patients.
Our study has several limitations. As a retro-
spective chart review, it suffers from the typical
disadvantages of this kind of studies like missing
information and non-standardizedway of documen-
tation. Since the patients were identified by being
treated in a neurological department, the inci-
dence of seizures is probably overestimated and
cannot be easily compared to that of patients
Seizures and epilepsy in HIV 33recruited from emergency wards or departments of
internal medicine.
We were not able to follow the patients over a
significant time period, therefore our study does not
have relevant outcome data. To further enhance our
knowledge about adequate diagnosis and therapy of
HIV-associated seizures, prospective studies focuss-
ing on therapy and outcome are needed.References
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